Anthem Biosciences Board of Directors
Get the latest insights into the leadership at Anthem Biosciences. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Ajay Bhardwaj | Chairman & Managing Director, Chief Executive Officer |
| Ganesh Sambasivam | Whole Time Director |
| K Ravindra Chandrappa | Whole Time Director |
| Satish Chander Subbanna | Nominee Director of Viridity Tone LLP |
| Ramesh Ramadurai | Non Executive Independent Director |
| Ravikant Uppal | Non Executive Independent Director |
| Subramanian Madhavan | Non Executive Independent Director |
| Shubha Kulkarni | Non Executive Independent Director |
| Divya Prasad | Company Secretary & Compliance Officer |
Anthem Biosciences FAQs
The board at Anthem Biosciences consists of experienced professionals, including Ajay Bhardwaj, Ganesh Sambasivam, and others, overseeing the company’s strategic and corporate governance.
Directors at Anthem Biosciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Ajay Bhardwaj is the current chairman at Anthem Biosciences.
Executive directors at Anthem Biosciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Anthem Biosciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Anthem Biosciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
